Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Kent

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Annals of the Rheumatic Diseases|March 3, 2016
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Johannes W J Bijlsma, Maarten de Wit, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Annals of the Rheumatic Diseases|October 2, 2020
EULAR definition of difficult-to-treat rheumatoid arthritisGyörgy Nagy, Nadia Mt Roodenrijs, Paco Mj Welsing, et al.
Rheumatology Advances in Practice|October 15, 2025
Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scopeStephanie F Ling, Joshua L Bennett, Vanessa J Reid, et al.
Annals of the Rheumatic Diseases|August 19, 2021
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritisGyörgy Nagy, Nadia M T Roodenrijs, Paco M J Welsing, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Annals of the Rheumatic Diseases|March 3, 2016
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Johannes W J Bijlsma, Maarten de Wit, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Annals of the Rheumatic Diseases|October 2, 2020
EULAR definition of difficult-to-treat rheumatoid arthritisGyörgy Nagy, Nadia Mt Roodenrijs, Paco Mj Welsing, et al.
Rheumatology Advances in Practice|October 15, 2025
Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scopeStephanie F Ling, Joshua L Bennett, Vanessa J Reid, et al.
Annals of the Rheumatic Diseases|August 19, 2021
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritisGyörgy Nagy, Nadia M T Roodenrijs, Paco M J Welsing, et al.
Pageof 4